Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma

Lazaridis, Lazaros; Schäfer, Niklas; Teuber‐Hanselmann, Sarah; Blau, Tobias; Schmidt, Teresa; Oster, Christoph; Weller, Johannes; Tzaridis, Theophilos; Pierscianek, Daniela; Keyvani, Kathy; Kleinschnitz, Christoph; Stuschke, Martin; Scheffler, Björn; Deuschl, Cornelius; Sure, Ulrich; Herrlinger, Ulrich; Kebir, Sied; Glas, Martin

doi:10.1007/s00432-019-03106-8

Cited by 29 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…105 The combined treatment of TTF and lomustine/TMZ has been shown to be safe and feasible in newly diagnosed GBM patients. 106 Two phase II clinical trials (NCT03405792, NCT03430791) aimed at studying the impact of TTF when delivered in combination with ICI in newly diagnosed and recurrent GBM (rGBM) are currently recruiting.…”

Section: Tumour Treating Fieldsmentioning

confidence: 99%

New hints towards a precision medicine strategy for IDH wild-type glioblastoma

et al. 2020

View full text Add to dashboard Cite

Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wildtype glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches.

show abstract

Section: Tumour Treating Fieldsmentioning

confidence: 99%

New hints towards a precision medicine strategy for IDH wild-type glioblastoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that TTFields therapy can synergistically enhance the antitumor effects of radiotherapy and chemotherapy, possibly by blocking homologous recombination repair in irradiated tumor cells harboring irradiation- or chemically induced DNA damage [ 46 , 48 , 50 ]. Recent findings in multiple cancer types suggest the use of TTFields as a synergistic therapy with radiation or DNA-damaging drugs to promote the apoptosis of cancer cells [ 50 , 51 , 52 , 53 , 54 ]. Furthermore, TTFields can be used to overcome multiple-drug-resistant cancer cells with ABC transporter overexpression [ 55 ] and even sensitize targeted therapy for human epidermal growth factor receptor 2 in trastuzumab-resistant breast cancers [ 56 ].…”

Section: Mechanisms Of Action Underlying the Effects Of Ttfieldsmentioning

confidence: 99%

“…The NOA-09/CeTeG trial found that the combination of lomustine and TMZ was superior to TMZ monotherapy in patients with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation (mMGMT) ndGBMs [ 91 ]. In 2020, Lazaridis et al [ 52 ] reported the results of a retrospective analysis of mMGMT ndGBM patients receiving TTFields in combination with lomustine and TMZ, with a median PFS of 20 months, revealing a potential clinical benefit.…”

Section: Clinical Studies Of Ttfields Treatment On Gbmsmentioning

confidence: 99%

Tumor-Treating Fields in Glioblastomas: Past, Present, and Future

Guo

Yang

et al. 2022

Cancers

View full text Add to dashboard Cite

Tumor-treating fields (TTFields), a noninvasive and innovative therapeutic approach, has emerged as the fourth most effective treatment option for the management of glioblastomas (GBMs), the most deadly primary brain cancer. According to on recent milestone randomized trials and subsequent observational data, TTFields therapy leads to substantially prolonged patient survival and acceptable adverse events. Clinical trials are ongoing to further evaluate the safety and efficacy of TTFields in treating GBMs and its biological and radiological correlations. TTFields is administered by delivering low-intensity, intermediate-frequency, alternating electric fields to human GBM function through different mechanisms of action, including by disturbing cell mitosis, delaying DNA repair, enhancing autophagy, inhibiting cell metabolism and angiogenesis, and limiting cancer cell migration. The abilities of TTFields to strengthen intratumoral antitumor immunity, increase the permeability of the cell membrane and the blood–brain barrier, and disrupt DNA-damage-repair processes make it a promising therapy when combined with conventional treatment modalities. However, the overall acceptance of TTFields in real-world clinical practice is still low. Given that increasing studies on this promising topic have been published recently, we conducted this updated review on the past, present, and future of TTFields in GBMs.

show abstract

“…The addition of TTFields to standard TMZ treatment in patients with HGG resulted in improved survival, with no negative impact on health-related quality of life other than itchy skin [89,90]. Furthermore, Lazaridis et al [91]suggested that TTFields combined with lomustine and temozolomide was superior to TTFields combined with temozolomide monotherapy in patients with HGG. And this analysis provided first indication that the combination of TTFields/lomustine/temozolomide was safe and feasible.…”

Section: Tumor-treating Fields (Ttfields)mentioning

confidence: 99%